Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US14070B3096
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000DZMK99
CAPR
Capricor Therapeutics, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Capricor Therapeutics, Inc.
ISIN
US14070B3096
TICKER
CAPR
MIC
XNAS
REUTERS
CAPR.OQ
BLOOMBERG
CAPR US
Wed, 12.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 12, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (th...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.08.2026       Capricor Therapeutics
US14070B3096

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.08.2026       Capricor Therapeutics
US14070B3096

Philadelphia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Kehoe Law Firm, P.C. announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates i...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.08.2026       Capricor Therapeutics
US14070B3096

San Diego, California--(Newsfile Corp. - August 11, 2026) - Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period"). The lawsuit alleges...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (th...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 10, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vi...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Capricor between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor" or the "Company") on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (th...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.08.2026       Capricor Therapeutics
US14070B3096

– Company to Host Conference Call on August 13, 2026, at 4:30 p.m. ET – – Company to Host Conference Call on August 13, 2026, at 4:30 p.m. ET –...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 09.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). A class action lawsuit has already been...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.08.2026       Capricor Therapeutics
US14070B3096

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 7, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The l...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.08.2026       Capricor Therapeutics
US14070B3096

San Diego, California--(Newsfile Corp. - August 6, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the "Class Period"), have until September 28, 2026 to seek appointment as lead plaintiff of...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 6, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (th...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). A class action lawsuit has already been...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 6, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vio...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.08.2026       Capricor Therapeutics
US14070B3096

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Capricor between December 17, 2025 and July 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 06.08.2026       Capricor Therapeutics
US14070B3096

Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026. Find out if you could qualify to recover your losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky....
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Capricor Therapeutics
US14070B3096

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ("“Capricor” or the “Company”) (NASDAQ: CAPR) and reminds investors of the September 29, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compan...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 5, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"). A class action lawsuit has already been...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.08.2026       Capricor Therapeutics
US14070B3096

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, both dates inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Caption...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Capricor Therapeutics
US14070B3096

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 incl...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Capricor Therapeutics
US14070B3096

Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). IF YOU...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged vio...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.08.2026       Capricor Therapeutics
US14070B3096

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) common stock between December 17, 2025 and July 26, 2026, inclusive (“the Class Period”).If you suffered a loss on your Capricor investments, you have u...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.If you invested in C...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor is a biotechnology company.For more information, submit a form, email attorney Phillip Kim, or g...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 3, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The l...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz reminds investors of the upcoming September 28, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Capricor Therapeutics, Inc. ("Capricor" or the Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclu...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.08.2026       Capricor Therapeutics
US14070B3096

The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of CAPR d...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 01.08.2026       Capricor Therapeutics
US14070B3096

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. (“Capricor” or “the Company”) (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 01.08.2026       Capricor Therapeutics
US14070B3096

New York, New York--(Newsfile Corp. - July 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Capricor Therapeutics Inc. (NASDAQ: CAPR) resulting from allegations that Capricor may have issued materially misleading business information to the inv...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 01.08.2026       Capricor Therapeutics
US14070B3096

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period").The lawsuit alleges that Capricor Therapeutics misled investors regarding the pa...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 01.08.2026       Capricor Therapeutics
US14070B3096

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Capricor Therapeutics
US14070B3096

Capricor (NASDAQ: CAPR) shares collapsed 60% to 70% on July 27, 2026 after FDA staff briefing documents raised significant concerns regarding the evidence supporting Deramiocel's efficacy ahead of the July 29, 2026 advisory committee meeting. CAPR shareholders who saw their investment drop after the FDA briefing documents are encouraged to act prom...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Capricor Therapeutics
US14070B3096

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). Capricor investors have until September 28, 2026 to file a lead plai...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Capricor Therapeutics
US14070B3096

Boston, Massachusetts--(Newsfile Corp. - July 31, 2026) - Block & Leviton is investigating Capricor Therapeutics (NASDAQ: CAPR) for potential securities law violations. Investors who have lost money in their Capricor Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Capricor Therapeutics
US14070B3096

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NA...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 31.07.2026       Capricor Therapeutics
US14070B3096

Glancy Prongay Wolke & Rotter LLP (“GPWR”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc., et al., on behalf of persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (“Capricor” or the...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Capricor Therapeutics
US14070B3096

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Capricor Therapeutics, Inc. (NASDAQ:CAPR) for potential securities fraud after its significant stock drop.If you invested in Capricor Therapeutics securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/capric...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Capricor Therapeutics
US14070B3096

Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased Capricor securities? If you purchased Capricor s...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.07.2026       Capricor Therapeutics
US14070B3096

SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee voted that available evidence did not suppor...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.07.2026       Capricor Therapeutics
US14070B3096

--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- --Randomized, Double-Blind, Placebo-Controlled HOPE-3 Phase 3 Trial (n=106) Met Primary Endpoint, with Deramiocel Slowing Upper Limb Function Decline by 54 Percent versus Placebo (PUL 2.0, p=0.03) and Showing Clinically Meaningful Ca...
Read more
Capricor Therapeutics
Technical Analysis Termsheets Terminal
Permalink